Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:CDXS's Cash-to-Debt is ranked higher than
85% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:CDXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CDXS' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.71  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.54
NAS:CDXS's Equity-to-Asset is ranked lower than
66% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:CDXS: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CDXS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.82  Med: 0.54 Max: 0.79
Current: 0.54
-1.82
0.79
Interest Coverage No Debt
NAS:CDXS's Interest Coverage is ranked higher than
81% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:CDXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:CDXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: -3.19
Beneish M-Score: -3.40
WACC vs ROIC
-9.97%
-4421.26%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -17.54
NAS:CDXS's Operating Margin % is ranked higher than
63% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:CDXS: -17.54 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CDXS' s Operating Margin % Range Over the Past 10 Years
Min: -151.36  Med: -28.36 Max: -6.65
Current: -17.54
-151.36
-6.65
Net Margin % -17.52
NAS:CDXS's Net Margin % is ranked higher than
64% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:CDXS: -17.52 )
Ranked among companies with meaningful Net Margin % only.
NAS:CDXS' s Net Margin % Range Over the Past 10 Years
Min: -153.86  Med: -29.71 Max: -7.97
Current: -17.52
-153.86
-7.97
ROE % -42.53
NAS:CDXS's ROE % is ranked lower than
55% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:CDXS: -42.53 )
Ranked among companies with meaningful ROE % only.
NAS:CDXS' s ROE % Range Over the Past 10 Years
Min: -68.88  Med: -37.42 Max: -15.76
Current: -42.53
-68.88
-15.76
ROA % -21.96
NAS:CDXS's ROA % is ranked higher than
56% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:CDXS: -21.96 )
Ranked among companies with meaningful ROA % only.
NAS:CDXS' s ROA % Range Over the Past 10 Years
Min: -52.02  Med: -25.02 Max: -7.11
Current: -21.96
-52.02
-7.11
ROC (Joel Greenblatt) % -264.24
NAS:CDXS's ROC (Joel Greenblatt) % is ranked higher than
54% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:CDXS: -264.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CDXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -472.46  Med: -262.99 Max: -35.45
Current: -264.24
-472.46
-35.45
3-Year Revenue Growth Rate 12.90
NAS:CDXS's 3-Year Revenue Growth Rate is ranked higher than
63% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:CDXS: 12.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CDXS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 12.9
Current: 12.9
0
12.9
3-Year EBITDA Growth Rate -50.30
NAS:CDXS's 3-Year EBITDA Growth Rate is ranked lower than
93% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:CDXS: -50.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:CDXS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -52.5 Max: 33.7
Current: -50.3
0
33.7
3-Year EPS without NRI Growth Rate -42.10
NAS:CDXS's 3-Year EPS without NRI Growth Rate is ranked lower than
87% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:CDXS: -42.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:CDXS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -47.2 Max: 45.6
Current: -42.1
0
45.6
GuruFocus has detected 3 Warning Signs with Codexis Inc $NAS:CDXS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CDXS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CDXS Guru Trades in Q1 2016

Jim Simons 807,000 sh (+7.16%)
» More
Q2 2016

CDXS Guru Trades in Q2 2016

Jim Simons 838,800 sh (+3.94%)
» More
Q3 2016

CDXS Guru Trades in Q3 2016

Jim Simons 872,200 sh (+3.98%)
» More
Q4 2016

CDXS Guru Trades in Q4 2016

Jim Simons 859,100 sh (-1.50%)
» More
» Details

Insider Trades

Latest Guru Trades with CDXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 541711    SIC: 8731
Compare:AMEX:OCX, NAS:GNCA, NAS:IMDZ, NAS:NYMX, NAS:ABUS, OTCPK:TSSNF, OTCPK:EGRN, OTCPK:IMMG, AMEX:PLX, NAS:CBMG, NAS:SBBP, NAS:FOMX, OTCPK:REDIF, NAS:REPH, AMEX:AST, NAS:FBIO, NAS:MDGL, NYSE:KDMN, NAS:ATHX, NAS:VTL » details
Traded in other countries:4QK.Germany,
Headquarter Location:USA
Codexis Inc is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. It has recently started to use its technology to develop biocatalysts for use in the fine chemicals markets.

Codexis is a biotech company focused on developing proprietary biocatalysts--enzymes or microbes that initiate or accelerate chemical reactions. Codex markets its biocatalyst products to a range of customers, primarily within the pharmaceutical industry. The company is currently engaged in a multi-year research and development collaboration with Shell Oil Products to develop advanced biofuels.

Ratios

vs
industry
vs
history
PB Ratio 9.18
CDXS's PB Ratio is ranked lower than
86% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CDXS: 9.18 )
Ranked among companies with meaningful PB Ratio only.
CDXS' s PB Ratio Range Over the Past 10 Years
Min: 0.84  Med: 3.16 Max: 10.69
Current: 9.18
0.84
10.69
PS Ratio 3.59
CDXS's PS Ratio is ranked higher than
74% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CDXS: 3.59 )
Ranked among companies with meaningful PS Ratio only.
CDXS' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 2.24 Max: 5.56
Current: 3.59
0.27
5.56
EV-to-EBIT -20.95
CDXS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CDXS: -20.95 )
Ranked among companies with meaningful EV-to-EBIT only.
CDXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -125.2  Med: -8.4 Max: -0.4
Current: -20.95
-125.2
-0.4
EV-to-EBITDA -44.65
CDXS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CDXS: -44.65 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -644.8  Med: -9.25 Max: 286.2
Current: -44.65
-644.8
286.2
Current Ratio 2.20
CDXS's Current Ratio is ranked lower than
71% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CDXS: 2.20 )
Ranked among companies with meaningful Current Ratio only.
CDXS' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.68 Max: 3.67
Current: 2.2
1.14
3.67
Quick Ratio 2.13
CDXS's Quick Ratio is ranked lower than
69% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CDXS: 2.13 )
Ranked among companies with meaningful Quick Ratio only.
CDXS' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.61 Max: 3.59
Current: 2.13
1.07
3.59
Days Inventory 37.94
CDXS's Days Inventory is ranked higher than
81% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CDXS: 37.94 )
Ranked among companies with meaningful Days Inventory only.
CDXS' s Days Inventory Range Over the Past 10 Years
Min: 31.91  Med: 45.73 Max: 66.14
Current: 37.94
31.91
66.14
Days Sales Outstanding 44.28
CDXS's Days Sales Outstanding is ranked higher than
65% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CDXS: 44.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDXS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 31.19  Med: 48.52 Max: 92.67
Current: 44.28
31.19
92.67
Days Payable 158.38
CDXS's Days Payable is ranked higher than
78% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. CDXS: 158.38 )
Ranked among companies with meaningful Days Payable only.
CDXS' s Days Payable Range Over the Past 10 Years
Min: 43.52  Med: 166.88 Max: 253.68
Current: 158.38
43.52
253.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
CDXS's 3-Year Average Share Buyback Ratio is ranked higher than
83% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CDXS: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CDXS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -143.1  Med: -2.4 Max: 0
Current: -2.5
-143.1
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 60.71
CDXS's Price-to-Net-Cash is ranked lower than
94% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. CDXS: 60.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CDXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.45  Med: 9.64 Max: 105.75
Current: 60.71
3.45
105.75
Price-to-Net-Current-Asset-Value 16.34
CDXS's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. CDXS: 16.34 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CDXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.19  Med: 6.35 Max: 17.69
Current: 16.34
2.19
17.69
Price-to-Tangible-Book 11.07
CDXS's Price-to-Tangible-Book is ranked lower than
83% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CDXS: 11.07 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CDXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 4.4 Max: 11.98
Current: 11.07
1.34
11.98
Price-to-Median-PS-Value 1.61
CDXS's Price-to-Median-PS-Value is ranked lower than
80% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CDXS: 1.61 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDXS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.38  Med: 0.74 Max: 1.8
Current: 1.61
0.38
1.8
Earnings Yield (Greenblatt) % -4.77
CDXS's Earnings Yield (Greenblatt) % is ranked higher than
54% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CDXS: -4.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.76  Med: 0 Max: 357.1
Current: -4.77
-5.76
357.1

More Statistics

Revenue (TTM) (Mil) $48.84
EPS (TTM) $ -0.22
Beta-2.03
Short Percentage of Float4.86%
52-Week Range $3.14 - 5.29
Shares Outstanding (Mil)41.26

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 43 73 86
EPS ($) -0.36 0.04 0.29
EPS without NRI ($) -0.36 0.04 0.29
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for CDXS

Headlines

Articles On GuruFocus.com
Codexis Announces Pricing of Public Offering of Common Stock Apr 07 2017 
Codexis Announces Proposed Public Offering of Common Stock Apr 06 2017 
Codexis Signs Second Multi-Year Agreement in Food Industry with Tate & Lyle Mar 31 2017 
Weekly 3-Year Lows Highlight: SEAS, AMTG, AHH, NCTY, CDXS Dec 30 2013 
Weekly CEO Buys Highlight: AKAM, DRC, MDRX, MTG, CDXS Mar 17 2013 
A New Beginning for Codexis? Mar 08 2013 
Weekly CFO Buys Highlight: ASNB, FXCM, CDXS, VTNC, BRS Sep 24 2012 

More From Other Websites
Codexis Announces Pricing of Public Offering of Common Stock Apr 07 2017
Codexis Announces Proposed Public Offering of Common Stock Apr 06 2017
Codexis Signs Second Multi-Year Agreement in Food Industry with Tate & Lyle Mar 31 2017
Codexis, Inc. :CDXS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
Codexis, Inc. :CDXS-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
Edited Transcript of CDXS earnings conference call or presentation 9-Mar-17 9:30pm GMT Mar 10 2017
Codexis reports 4Q loss Mar 09 2017
Codexis Reports 2016 Fourth Quarter and Full Year Financial Results Mar 09 2017
3 Top Stocks Under $5 Mar 08 2017
Codexis to Hold 2016 Fourth Quarter and Full Year Conference Call on March 9 Mar 02 2017
Should Codexis (CDXS) Be On Your Radar Now? Jan 09 2017
The Zacks Analyst Blog Highlights: Codexis, EMCORE, Intevac, Organovo Holdings and StarTek Jan 04 2017
5 of the Best Stocks Under $10 for 2017 Jan 03 2017
ETFs with exposure to Codexis, Inc. : December 14, 2016 Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)